Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), has made a significant move in the pharmaceutical industry.The company has expanded its drug metabolism and pharmacokinetics (DMPK) capabilities. This expansion is aimed at offering global big pharma
Fabio Russo, Chief Procurement Officer
AlfaSigma explains the company’s new procurement operating model.
Biovian and 3P Biopharmaceuticals, biologics Contract Development and Manufacturing Organisations (CDMOs), announced their combination to establish a new pan-European leader in their field. This strategic move was backed by their common shareholder, Keensight Capital. The newly formed group, named 3PBIOVIAN, will offer
Marga Viñes Senior Business Development Manager for Grifols contract manufacturing, explains the drug development and manufacturing services that they offer to customers.
AustinPx, a CDMO specialising in bioavailability enhancement of orally delivered small molecule drug candidates, and Microsize, a leading active pharmaceutical ingredient enhancement CDMO, announced a strategic partnership on January 31, 2024. The partnership aims to accelerate the commercial application of AustinPx’s
Exo Biologics, a Belgian biotech company, has announced the launch of ExoXpert, a new CDMO specialising in exosomes. This move comes as a response to the increasing global demand for exosomes, tiny vesicles that play a crucial role in cell-to-cell communication.
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
